Noxopharm's phase I clinical trial of TBK1 inhibitor idronoxil shows that patients with new coronary pneumonia have anti-inflammatory response

Noxopharm(ASX:NOX), an Australian clinical-stage drug development company , has released preliminary headline data for its NOXCOVID phase I clinical trial, which aims to investigate whether TBK1 (TANK-binding kinase 1) inhibitor idronoxil ( Veyonda ^® ) is suitable as an anti- Inflammatory drugs are used for patients with moderate new coronary pneumonia disease

Blocking TBK1 has two important meanings: (i) it can block the dysfunctional immune response to RNA viruses (such as coronavirus and influenza virus) ; (ii) it is expected to avoid standard anti-inflammatory drugs (such as prednisone and dihydrochloride).

Graham Kelly, CEO and Managing Director of Noxopharm said: "The results of the NOXCOVID Phase I clinical trial are very encouraging, and Veyonda has played an important role in it, as a large proportion of patients are experiencing increased inflammation

Marcel Nold , MD , professor of pediatric immunology at Monash University and the Hudson Institute, and a pediatrician at Monash Children’s Hospital , said: “Based on what is currently known, the characteristics of Veyonda make it possible to fill the gap in our new coronary pneumonia treatment drug lineup.